Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
Under the terms of the license agreement,
This collaboration is intended to support the success of
Locust Walk acted as the exclusive financial advisor to Corsair in the transaction.
About Pulmonary Arterial Hypertension (PAH) and Treprostinil
PAH is a serious, progressive and ultimately fatal disease that affects the blood vessels, lungs and heart, causing shortness of breath, markedly reducing quality of life. Current treatments offer some symptomatic relief and some have been shown to delay disease progression, but there is no known cure.
PAH is an orphan disease that affects an estimated 500,000 people globally. In
Patients with PAH may not produce enough prostacyclin, a natural substance that keeps blood vessels open and working properly. This makes it more difficult for the body to get the oxygen it needs. Treprostinil is a prostacyclin analogue marketed by
Prodrug formulations of treprostinil are intended to enable subcutaneous delivery without the infusion site pain currently associated with subcutaneous treprostinil. A prodrug is a metabolically inactive compound that, after administration, metabolizes into an active compound. These prodrugs are intended to be inactive in the subcutaneous tissue, which should eliminate site pain. Once the prodrug is absorbed into the blood, it metabolizes into treprostinil.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the efforts by Corsair and
REMOPRO is a trademark of
United Therapeutics Contact - James Edgemond, Phone: (301) 608-9292, E-mail: email@example.com; Corsair Contact - Amanda Hayward, Phone: (650) 273-5748, E-Mail: firstname.lastname@example.org